ATE356149T1 - Bispezifische antikörper gegen cd19 und cd16 und deren verwendung - Google Patents
Bispezifische antikörper gegen cd19 und cd16 und deren verwendungInfo
- Publication number
- ATE356149T1 ATE356149T1 AT01127061T AT01127061T ATE356149T1 AT E356149 T1 ATE356149 T1 AT E356149T1 AT 01127061 T AT01127061 T AT 01127061T AT 01127061 T AT01127061 T AT 01127061T AT E356149 T1 ATE356149 T1 AT E356149T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- polynucleotides
- vectors
- human
- antibodies against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127061A EP1314741B1 (de) | 2001-11-14 | 2001-11-14 | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356149T1 true ATE356149T1 (de) | 2007-03-15 |
Family
ID=8179236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01127061T ATE356149T1 (de) | 2001-11-14 | 2001-11-14 | Bispezifische antikörper gegen cd19 und cd16 und deren verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050089519A1 (de) |
| EP (1) | EP1314741B1 (de) |
| JP (1) | JP4373788B2 (de) |
| AT (1) | ATE356149T1 (de) |
| AU (1) | AU2002356601A1 (de) |
| DE (1) | DE60127143T2 (de) |
| ES (1) | ES2283368T3 (de) |
| WO (1) | WO2003048209A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP1354600A1 (de) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antikörperkombination verwendbar für Tumortherapie |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
| EP2418223A3 (de) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Einkettige, multivalente Bindungsproteine mit Effektorfunktion |
| JP5825756B2 (ja) | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP1903115B1 (de) * | 2006-09-22 | 2011-03-09 | Wacker Chemie AG | Verfahren zur fermentativen Herstellung von Antikörpern |
| EP2014680A1 (de) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Rekombinante, einkettige, trivalente trispezifische oder bispezifische Antikörperderivate |
| DE102007041834A1 (de) * | 2007-09-03 | 2009-03-05 | Siemens Ag | Arzneimittel zur Behandlung eines Karzinoms |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2640750A1 (de) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Mittel und verfahren zur behandlung von mit bcma-expression korrelierenden erkrankungen |
| CA2820782A1 (en) * | 2010-12-10 | 2012-06-14 | Merck Patent Gmbh | Bispecific aptamers mediating tumour cell lysis |
| EP2729488A4 (de) * | 2011-07-06 | 2015-01-14 | Medimmune Llc | Verfahren zur herstellung multimerer polypeptide |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| EP2762496A1 (de) | 2013-02-05 | 2014-08-06 | EngMab AG | Verfahren zur Auswahl von Antikörpern gegen BCMA |
| ES2667420T3 (es) | 2013-02-05 | 2018-05-10 | Engmab Sàrl | Anticuerpos biespecíficos contra cd3epsilon y bcma |
| EP2789630A1 (de) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispezifische Antikörper gegen CD3e und ROR1 |
| AU2015329965A1 (en) | 2014-10-09 | 2017-04-27 | Engmab Sàrl | Bispecific antibodies against CD3epsilon and ROR1 |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| EP3670535A1 (de) | 2015-08-03 | 2020-06-24 | EngMab Sàrl | Monoklonale antikörper gegen bcma |
| HUE066644T2 (hu) | 2015-09-15 | 2024-08-28 | Acerta Pharma Bv | CD19-inhibitor és BTK-inhibitor terápiás kombinációi |
| MX2018003292A (es) | 2015-09-21 | 2018-08-01 | Aptevo Res & Development Llc | Polipéptidos de unión a cd3. |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| KR102761077B1 (ko) * | 2015-10-02 | 2025-02-04 | 에프. 호프만-라 로슈 아게 | 높은 친화성을 갖는 항-인간 cd19 항체 |
| EP3502142B1 (de) | 2016-06-22 | 2021-10-27 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Bispezifischer antikörper und antikörperkonjugat für tumortherapie und verwendung davon |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| AU2018228719B2 (en) * | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
| WO2019118266A1 (en) * | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020089437A1 (en) | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| WO2020141145A1 (en) | 2018-12-30 | 2020-07-09 | F. Hoffmann-La Roche Ag | Anti-rabbit cd19 antibodies and methods of use |
| RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
| CN116745324A (zh) | 2021-01-27 | 2023-09-12 | 信达生物制药(苏州)有限公司 | 针对cd16a的单域抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| CZ121599A3 (cs) * | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
-
2001
- 2001-11-14 DE DE60127143T patent/DE60127143T2/de not_active Expired - Lifetime
- 2001-11-14 ES ES01127061T patent/ES2283368T3/es not_active Expired - Lifetime
- 2001-11-14 AT AT01127061T patent/ATE356149T1/de active
- 2001-11-14 EP EP01127061A patent/EP1314741B1/de not_active Expired - Lifetime
-
2002
- 2002-11-14 AU AU2002356601A patent/AU2002356601A1/en not_active Abandoned
- 2002-11-14 WO PCT/EP2002/012776 patent/WO2003048209A1/en not_active Ceased
- 2002-11-14 US US10/495,508 patent/US20050089519A1/en not_active Abandoned
- 2002-11-14 JP JP2003549396A patent/JP4373788B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4373788B2 (ja) | 2009-11-25 |
| WO2003048209A1 (en) | 2003-06-12 |
| ES2283368T3 (es) | 2007-11-01 |
| DE60127143D1 (de) | 2007-04-19 |
| EP1314741B1 (de) | 2007-03-07 |
| EP1314741A1 (de) | 2003-05-28 |
| US20050089519A1 (en) | 2005-04-28 |
| DE60127143T2 (de) | 2007-11-15 |
| JP2005517392A (ja) | 2005-06-16 |
| AU2002356601A1 (en) | 2003-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE356149T1 (de) | Bispezifische antikörper gegen cd19 und cd16 und deren verwendung | |
| BR0209989A (pt) | Plataformas baseadas em cromossomas | |
| NO20005296D0 (no) | CD19xCD3-spesifikke polypeptider og anvendelser derav | |
| NO346167B1 (no) | Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning | |
| WO2007002223A3 (en) | Cd19 antibodies and their uses | |
| ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
| ATE429450T1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
| DE60237851D1 (de) | Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung | |
| ATE157990T1 (de) | Monoklonale antikörper gegen den humanen alpha/beta-t-zellenrezeptor, ihre herstellung und verwendung | |
| DK0602126T3 (da) | Immunoglobulinvarianter til specifikke FC epsilon-receptorer | |
| CY1113145T1 (el) | Μορια υποδοχεα θυμικης στρωματικης λεμφοποιητινης και χρησεις αυτων | |
| ATE551363T1 (de) | Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen | |
| DK0980429T3 (da) | Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder | |
| CY1110505T1 (el) | Ανθρωπινα αντισωματα dr4 και χρησεις αυτων | |
| DE60210413D1 (de) | Zusammensetzungen zur immunisierung sowie deren verwendung | |
| PL369741A1 (en) | Immunocytokines with modulated selectivity | |
| DE602004007257D1 (de) | Hydroxy-diaryl-carbaldehyd- oxim-verbindungen und deren verwendung als oestrogenwirksame substanzen | |
| WO2006076691A8 (en) | Irta-2 antibodies and their uses | |
| WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
| ATE267596T1 (de) | Cyanidinzusammensetzungen und deren therapeutische und diagnostische verwendungen | |
| DE60038739D1 (de) | Somatostatin analoge, deren radiomarkierte derivate und deren verwendung | |
| ATE171473T1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 | |
| ATE157401T1 (de) | Monoklonale antikörper gegen humanes ige | |
| IL150115A (en) | Isolated antibody that binds to rg1 polypeptides, immunosuppressant containing this antibody, antibody uses, and methods utilizing it | |
| ATE397662T1 (de) | Neues polypeptid, dafür kodierende dna und deren verwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1314741 Country of ref document: EP |